Janssen
Manufacturing · New Jersey, United States · 40,000 Employees
View Company Info for Free
About
Headquarters
1125 Bear Tavern Rd, Titusville, New Jersey, 08...Website
www.janssen.comRevenue
$13.5 BillionIndustry
Most Recent Scoops
Who is Janssen
Janssen PMP (https://www.janssenpmp.com/) is a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johns on. The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Janssen PMP is a long-established world leader in the development and formulation of new and highly effective active substances and end-use products for the protection of materials and food, especially fruits and vegetables. With more than 50 years' experience in Post-Harvest treatments and Plant Protection, Janssen PMP has developed strong technical and commercial expertise. Through protection of our surroundings, we aim to protect the health and well-being of the people in the environment in which our products are being used.Read more
Popular SearchesJanssen Global Services LLCJanssen Pharmaceuticals IncJanssenJanssen IncJanssen Research & Development LLCSIC Code 28,283NAICS Code 32,325Show moreJanssen Org Chart
Is Janssen your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Check out if Janssen is spiking on competitors!
Check if Janssen has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Janssen recently announced quarterly report
Funding: Get notified immidiatlly once Janssen has new funding data
Janssen, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Janssen
Click to see if Janssen had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Janssen launches new products
Recommended Actions
Find VP level buyers at Janssen
Find 2 more new buyers
Similar Companies to Janssen
Analyze insights from companies similar to Janssen and make strategic comparisons based on performance, financial data, growth and unique benchmarks.
- Pfizer88,000$54.9B
- Merck & Co70,000$61.4B
- MSD United States69,000$10.1B
- Novartis76,057$47.7B
- Johnson & Johnson Services Inc131,900$86.6B
- Daiichi Sankyo16,458$10.1B
- Takeda47,347$26.9B
- Teva Pharmaceuticals USA, Inc.37,000$334.6M
More similar companies
Janssen Email Formats
Janssen uses at least 5 email formats with first initials + last (ex. JSmith@its.jnj.com) being used 35.2% of the time
Janssen Email Formats | Percentage | |
---|---|---|
first initials + last | JSmith@its.jnj.com | 35.2% |
first initials + last initials | JSmith@its.jnj.com | 15% |
first initials + last | JSmith@janssen.com | 4% |
first.last | John.Smith@janssen.com | 3.9% |
first initials + last | JSmith@jnj.com | 0.7% |
Get Verified Emails
Janssen Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Janssen Tech Stack
A closer look at the technologies used by Janssen
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Most Recent Scoops
Janssen News & Media
RYBREVANT®▼ (amivantamab) plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
New longer-term data from the MARIPOSA study confirm superior outcomes of amivantamab plus lazertinib regimen compared to osimertinib monotherapy as first-line therapy1European Commission approves RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, have until now faced a poor prognosis and limited treatment options after disease progression on an EGFR TKI1,2,3,4 CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib1,2,3,4 Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH
Frequently Asked Questions Regarding Janssen
Janssen PMP (https://www.janssenpmp.com/) is a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, inf... Read More